Detalhe da pesquisa
1.
A preliminary investigation of circulating extracellular vesicles and biomarker discovery associated with treatment response in head and neck squamous cell carcinoma.
BMC Cancer
; 19(1): 373, 2019 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31014274
2.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892145
3.
High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.
Head Neck
; 41(5): 1199-1205, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30803092
4.
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.
Oral Oncol
; 98: 48-52, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31539757
5.
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Oral Oncol
; 97: 82-91, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31450171
6.
Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Sci Rep
; 9(1): 3209, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824880
7.
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
JAMA Oncol
; 5(8): 1170-1180, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194247
8.
Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?
Pathol Oncol Res
; 24(4): 931-935, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29130149
9.
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
Oncotarget
; 8(32): 53288-53301, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881811
10.
MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Oncotarget
; 8(6): 9911-9921, 2017 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28039483
11.
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
J Immunol Res
; 2016: 9839685, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27747247
12.
Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
Recent Pat Anticancer Drug Discov
; 11(2): 170-83, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26955963
13.
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Cell Oncol (Dordr)
; 39(3): 253-63, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26920031
14.
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Head Neck
; 38 Suppl 1: E970-80, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26031625
15.
Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer.
Anticancer Res
; 34(10): 5599-607, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25275062
16.
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
Support Care Cancer
; 16(7): 841-6, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17960431